Reported Earnings • Jun 12
Full year 2026 earnings released: EPS: JP¥34.88 (vs JP¥25.20 loss in FY 2025) Full year 2026 results: EPS: JP¥34.88 (up from JP¥25.20 loss in FY 2025). Revenue: JP¥10.9b (up 57% from FY 2025). Net income: JP¥4.16b (up JP¥6.66b from FY 2025). Profit margin: 38% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Annonce • Jun 11
3-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026 3-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to JP¥474, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 153% over the past three years. Annonce • May 10
3-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 2026 3-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026 New Risk • Apr 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding). Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥585, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 41x in the Biotechs industry in Asia. Total returns to shareholders of 257% over the past three years. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment deteriorates as stock falls 34% After last week's 34% share price decline to JP¥470, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 37x in the Biotechs industry in Asia. Total returns to shareholders of 106% over the past three years. Reported Earnings • Mar 13
Third quarter 2026 earnings released: EPS: JP¥5.39 (vs JP¥5.66 loss in 3Q 2025) Third quarter 2026 results: EPS: JP¥5.39 (up from JP¥5.66 loss in 3Q 2025). Revenue: JP¥2.54b (up 42% from 3Q 2025). Net income: JP¥653.0m (up JP¥1.24b from 3Q 2025). Profit margin: 26% (up from net loss in 3Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. New Risk • Dec 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (21% accrual ratio). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Reported Earnings • Dec 16
Second quarter 2026 earnings released: EPS: JP¥7.96 (vs JP¥0.18 loss in 2Q 2025) Second quarter 2026 results: EPS: JP¥7.96 (up from JP¥0.18 loss in 2Q 2025). Revenue: JP¥2.61b (up 46% from 2Q 2025). Net income: JP¥936.0m (up JP¥954.0m from 2Q 2025). Profit margin: 36% (up from net loss in 2Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Annonce • Oct 20
3-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough 3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine. Annonce • Sep 23
3-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 2025 3-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025 Reported Earnings • Sep 12
First quarter 2026 earnings released: EPS: JP¥6.88 (vs JP¥9.20 loss in 1Q 2025) First quarter 2026 results: EPS: JP¥6.88 (up from JP¥9.20 loss in 1Q 2025). Revenue: JP¥2.19b (up 48% from 1Q 2025). Net income: JP¥765.0m (up JP¥1.55b from 1Q 2025). Profit margin: 35% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Jul 11
3-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc. On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction. Annonce • Jul 09
3-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 2025 3-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025 Reported Earnings • Jun 14
Full year 2025 earnings released: JP¥25.20 loss per share (vs JP¥3.48 loss in FY 2024) Full year 2025 results: JP¥25.20 loss per share (further deteriorated from JP¥3.48 loss in FY 2024). Revenue: JP¥6.93b (up 51% from FY 2024). Net loss: JP¥2.50b (loss widened JP¥2.25b from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annonce • Jun 12
3-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025 3-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025. Annonce • Apr 11
3-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 2025 3-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025 Reported Earnings • Mar 14
Third quarter 2025 earnings released: JP¥5.66 loss per share (vs JP¥7.18 loss in 3Q 2024) Third quarter 2025 results: JP¥5.66 loss per share. Revenue: JP¥1.79b (up 56% from 3Q 2024). Net loss: JP¥588.0m (loss widened 5.0% from 3Q 2024). New Risk • Mar 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Annonce • Jan 17
3-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 2025 3-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025 New Risk • Dec 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (JP¥13.7b market cap, or US$87.4m). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (JP¥12.6b market cap, or US$82.1m). Reported Earnings • Dec 13
Second quarter 2025 earnings released: JP¥0.18 loss per share (vs JP¥2.08 loss in 2Q 2024) Second quarter 2025 results: JP¥0.18 loss per share (improved from JP¥2.08 loss in 2Q 2024). Revenue: JP¥1.79b (up 77% from 2Q 2024). Net loss: JP¥18.0m (loss narrowed 88% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Annonce • Oct 29
3-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 2024 3-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024 Reported Earnings • Sep 17
First quarter 2025 earnings released: JP¥9.20 loss per share (vs JP¥0.12 profit in 1Q 2024) First quarter 2025 results: JP¥9.20 loss per share (down from JP¥0.12 profit in 1Q 2024). Revenue: JP¥1.49b (up 80% from 1Q 2024). Net loss: JP¥787.0m (down JP¥795.0m from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Annonce • Aug 03
3-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 2024 3-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024 New Risk • Jul 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.9b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Market cap is less than US$100m (JP¥14.2b market cap, or US$92.1m). Reported Earnings • Jun 17
Full year 2024 earnings released: JP¥3.48 loss per share (vs JP¥40.62 loss in FY 2023) Full year 2024 results: JP¥3.48 loss per share (improved from JP¥40.62 loss in FY 2023). Revenue: JP¥4.59b (up 98% from FY 2023). Net loss: JP¥255.0m (loss narrowed 90% from FY 2023). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Annonce • Jun 15
3-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024 3-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024. Annonce • May 17
3-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 2024 3-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024 Annonce • Apr 04
3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc. On April 4, 2024, 3-D Matrix, Ltd., closed the transaction. Annonce • Mar 20
3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc. 3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company. Reported Earnings • Mar 14
Third quarter 2024 earnings released: JP¥7.18 loss per share (vs JP¥27.66 loss in 3Q 2023) Third quarter 2024 results: JP¥7.18 loss per share (improved from JP¥27.66 loss in 3Q 2023). Revenue: JP¥1.15b (up 100% from 3Q 2023). Net loss: JP¥560.0m (loss narrowed 67% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Annonce • Mar 01
3-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 2024 3-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024 Reported Earnings • Dec 16
Second quarter 2024 earnings released: JP¥2.08 loss per share (vs JP¥2.42 profit in 2Q 2023) Second quarter 2024 results: JP¥2.08 loss per share (down from JP¥2.42 profit in 2Q 2023). Revenue: JP¥1.01b (up 80% from 2Q 2023). Net loss: JP¥147.0m (down 202% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Annonce • Nov 13
3-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 2023 3-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023 New Risk • Sep 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (JP¥10.9b market cap, or US$73.5m). Annonce • Sep 02
3-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 2023 3-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023 Reported Earnings • Aug 02
Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022) Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. New Risk • Jul 20
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥9.98b market cap, or US$71.6m). New Risk • Jul 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥10.6b market cap, or US$73.7m). Annonce • Jun 16
3-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023 3-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023. Reported Earnings • Jun 16
Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022) Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Annonce • May 10
3-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 2023 3-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023 Reported Earnings • Mar 18
Third quarter 2023 earnings released: JP¥27.66 loss per share (vs JP¥15.16 loss in 3Q 2022) Third quarter 2023 results: JP¥27.66 loss per share (further deteriorated from JP¥15.16 loss in 3Q 2022). Revenue: JP¥574.0m (up 59% from 3Q 2022). Net loss: JP¥1.70b (loss widened 106% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Annonce • Feb 16
3-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 2023 3-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023 Reported Earnings • Dec 15
Second quarter 2023 earnings released: EPS: JP¥2.42 (vs JP¥9.09 loss in 2Q 2022) Second quarter 2023 results: EPS: JP¥2.42 (up from JP¥9.09 loss in 2Q 2022). Revenue: JP¥561.0m (up 87% from 2Q 2022). Net income: JP¥144.0m (up JP¥589.0m from 2Q 2022). Profit margin: 26% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Nov 09
3-D Matrix, Ltd. to Report Q2, 2023 Results on Dec 13, 2022 3-D Matrix, Ltd. announced that they will report Q2, 2023 results on Dec 13, 2022 Annonce • Oct 19
3-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc. On October 17, 2022, 3-D Matrix, Ltd. closed the transaction. Annonce • Oct 01
3-D Matrix, Ltd. announced that it expects to receive ¥2.059835568 billion in funding from CVI Investments, Inc. 3-D Matrix, Ltd. announced a private placement of 6th unsecured convertible bonds, with a face of ¥100 each, at a price of ¥100 per corporate bond for gross proceeds of ¥2,050,000,000 with stock acquisition rights and 55,256 33rd stock acquisition rights at a price of ¥178 for gross proceeds of ¥9,835,568; for an aggregate gross proceeds of ¥2,059,835,568 on September 30, 2022. The transaction will include participation from returning investor CVI Investments, Inc. The funding will be raised through third-party allotment. The bonds will be convertible at an initial conversion price of ¥371 into 5,525,606 shares from October 17, 2025 to April 17, 2026 and matures on October 22, 2026. The bonds carry interest rate of 2%. The bonds are redeemable. The exercise period for 33rd stock acquisition rights is from October 18, 2022 to October 18, 2027. They carry an initial exercise price of ¥371 each. The transaction has been approved by the board of directors of directors. The transaction is expected to close on October 17, 2022. Reported Earnings • Sep 16
First quarter 2023 earnings released: JP¥9.24 loss per share (vs JP¥17.54 loss in 1Q 2022) First quarter 2023 results: JP¥9.24 loss per share (improved from JP¥17.54 loss in 1Q 2022). Revenue: JP¥423.0m (up 24% from 1Q 2022). Net loss: JP¥524.0m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Annonce • Aug 03
3-D Matrix, Ltd. to Report Q1, 2023 Results on Sep 14, 2022 3-D Matrix, Ltd. announced that they will report Q1, 2023 results on Sep 14, 2022 Reported Earnings • Aug 03
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 256% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annonce • Jun 16
3-D Matrix, Ltd., Annual General Meeting, Jul 28, 2022 3-D Matrix, Ltd., Annual General Meeting, Jul 28, 2022. Reported Earnings • Jun 15
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 546% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Annonce • May 13
3-D Matrix, Ltd. to Report Fiscal Year 2022 Results on Jun 14, 2022 3-D Matrix, Ltd. announced that they will report fiscal year 2022 results on Jun 14, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Apr 13
3-D Matrix, Ltd. announced that it expects to receive ¥1.7650936 billion in funding from CVI Investments, Inc. 3-D Matrix, Ltd. announced a private placement of approximately 17,650,936 5th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 1,765,093,600 and 31st stock acquisition rights on April 11, 2022. The funding will be raised through third-party allotment. The transaction is expected to close on April 27, 2022. The stock acquisition rights will be convertible at a initial conversion price of JPY 441 into 4,002,479 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry interest rate of 2% and have a redemption date of June 5, 2026. The application period for 31st stock acquisition rights is on April 27, 2022. They carry an initial exercise price of JPY 441 each. The transaction has been approved by the board of directors of directors. Reported Earnings • Mar 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: JP¥15.16 loss per share (down from JP¥11.52 loss in 3Q 2021). Revenue: JP¥360.0m (up 55% from 3Q 2021). Net loss: JP¥828.0m (loss widened 73% from 3Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 139%, compared to a 2,909% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 17
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: JP¥9.09 loss per share (up from JP¥16.66 loss in 2Q 2021). Revenue: JP¥300.0m (up 14% from 2Q 2021). Net loss: JP¥445.0m (loss narrowed 35% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 135%, compared to a 3,108% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 18
First quarter 2022 earnings released: JP¥17.54 loss per share (vs JP¥11.16 loss in 1Q 2021) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: JP¥340.0m (up 63% from 1Q 2021). Net loss: JP¥797.0m (loss widened 95% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annonce • Aug 28
3-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc. On August 27, 2021, 3-D Matrix, Ltd. closed the transaction. Annonce • Aug 12
3-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc. 3-D Matrix, Ltd. announced a private placement of approximately 8,000,000 4th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 800,000,000 and 65,000 30th stock acquisition rights for gross proceeds of JPY 14,430,000, for aggregate gross proceeds of JPY 2,609,000 on August 11, 2021. The funding will be raised through third-party allotment. The transaction is expected to close on August 27, 2021. The stock acquisition rights will be convertible at a initial conversion price of JPY 311 into 2,572,347 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry no interest rate and have a redemption date of October 4, 2025. The application period for 30th stock acquisition rights is from August 30, 2021 to August 29, 2022. They carry an initial exercise price of JPY 280 each. The transaction has been approved by the board of directors of directors. Annonce • Aug 05
3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. 3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. on August 3, 2021. As part of the transaction, 3-D Matrix, Ltd. will transfer patent and license to PURMX Therapeutics Co., Ltd. Reported Earnings • Aug 03
Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 18
Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 18
Third quarter 2021 earnings released: JP¥11.52 loss per share (vs JP¥22.05 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥233.0m (up 23% from 3Q 2020). Net loss: JP¥479.0m (loss narrowed 28% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Annonce • Mar 07
3-D Matrix, Ltd. to Report Q3, 2021 Results on Mar 16, 2021 3-D Matrix, Ltd. announced that they will report Q3, 2021 results on Mar 16, 2021 Is New 90 Day High Low • Dec 25
New 90-day low: JP¥280 The company is down 32% from its price of JP¥410 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Reported Earnings • Dec 17
Second quarter 2021 earnings released: JP¥16.66 loss per share The company reported a solid second quarter result with improved revenues and control over expenses, though losses increased. Second quarter 2021 results: Revenue: JP¥263.0m (up 50% from 2Q 2020). Net loss: JP¥679.0m (loss widened 6.6% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Dec 08
New 90-day low: JP¥339 The company is down 14% from its price of JP¥395 on 09 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Annonce • Dec 05
3-D Matrix, Ltd. to Report Q2, 2021 Results on Dec 15, 2020 3-D Matrix, Ltd. announced that they will report Q2, 2021 results on Dec 15, 2020 Annonce • Nov 11
3-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc. 3-D Matrix, Ltd. (JASDAQ:7777) announced that it has entered into purchase agreement to issue 561,700 shares at issue price of ¥356 per share for gross proceeds of ¥199,965,200, 55,000 27th stock acquisition rights at issue price of ¥291 per right for gross proceeds of ¥16,105,000, 10,000 28th stock acquisition rights at issue price of ¥10 per right for gross proceeds of ¥100,000; for an aggregate gross proceeds of ¥216,170,200 on November 10, 2020. The transaction includes participation from returning investor, CVI Investments, Inc. The company will raise money through third party allotment. The 27th stock acquisition rights can be exercisable to purchase 5,500,000 shares of the company at an exercise price of ¥356 per share and 28th stock acquisition rights can be exercise to purchase 1,000,000 shares of the company at an exercise price of ¥435 per share. The 27th stock acquisition rights can be exercised from November 27, 2020 to May 26, 2022 and 28th stock acquisition rights can be exercised from November 27, 2020 to November 26, 2024. The company incurred issuance expense of ¥25,000,000 in relation to the transaction. The transaction is expected to close on November 26, 2020. The transaction has been approved by the board of directors of the company. Is New 90 Day High Low • Nov 01
New 90-day low: JP¥378 The company is down 3.0% from its price of JP¥389 on 03 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Annonce • Sep 04
3-D Matrix, Ltd. to Report Q1, 2021 Results on Sep 14, 2020 3-D Matrix, Ltd. announced that they will report Q1, 2021 results on Sep 14, 2020